Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell CarcinomaJonathan D. Schoenfeld, Robert I. Haddad, Ana Lako et al.|JAMA Oncology|2020Cited by 350
Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United StatesBrandon A. Mahal, Danielle N. Margalit, Paul J. Catalano et al.|Cancer Epidemiology Biomarkers & Prevention|2019Cited by 230
Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus StatementDavid Thomson, Sue S. Yom, David A. Palma et al.|International Journal of Radiation Oncology*Biology*Physics|2020Cited by 211
A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic CarcinomaUmair Mahmood, Jonathan D. Schoenfeld, Andrew Bang et al.|International Journal of Radiation Oncology*Biology*Physics|2020Cited by 111
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and NeckGlenn J. Hanna, Robert I. Haddad, Anne O’Neill et al.|Clinical Cancer Research|2021Cited by 104